Literature DB >> 19940744

Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children.

Marcel Yotebieng1, Annelies Van Rie, Harry Moultrie, Tammy Meyers.   

Abstract

OBJECTIVES: Construct percentile curves for 6-month gain in weight, height, CD4 cell count, and CD4 percentage (CD4%) in children initiating ART, and to assess the association between lower percentiles and subsequent ART responses.
DESIGN: Cohort of 1394 HIV-infected children initiating ART between April 2004 and March 2008, Johannesburg, South Africa
METHODS: The generalized additive model for location, scale, and shape was used to construct percentile curves for 6-month gain in weight, height, CD4 cell count, and CD4%. Cox proportional models were used to assess the association between lower percentiles of each distribution and death, virological suppression, and treatment failure between 6 to 36 months post-ART initiation.
RESULTS: Lower percentiles for gain in weight, CD4, and CD4% count after 6 months of ART, but not height, were associated with poor subsequent treatment outcomes independent of baseline characteristics, with increasing strength of association as percentiles decreased. Age-specific 6-month post-ART weight gain in our cohort was substantially higher compared with 6-month weight gain in non-HIV-infected American children of the Fels Institute cohort and the attained weight-for-age at 6 months post-ART plotted on WHO weight-for-age growth charts were not associated with subsequent treatment outcomes.
CONCLUSION: Gain in CD4% in the first 6 months of ART was the best predictor of poor subsequent ART outcomes. In areas with limited access to CD4%, weight gain post-ART using our newly developed reference distributions for HIV-infected children on ART is a good alternative to CD4%, and clearly superior to the commonly used 'Road-to-Health' weight-for-age charts.

Entities:  

Mesh:

Year:  2010        PMID: 19940744      PMCID: PMC2939835          DOI: 10.1097/QAD.0b013e328332d5ca

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

1.  Quantile regression methods for reference growth charts.

Authors:  Ying Wei; Anneli Pere; Roger Koenker; Xuming He
Journal:  Stat Med       Date:  2006-04-30       Impact factor: 2.373

2.  Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.

Authors:  J A Englund; C J Baker; C Raskino; R E McKinney; B Petrie; M G Fowler; D Pearson; A Gershon; G D McSherry; E J Abrams; J Schliozberg; J L Sullivan
Journal:  N Engl J Med       Date:  1997-06-12       Impact factor: 91.245

3.  Incremental growth tables: supplementary to previously published charts.

Authors:  R N Baumgartner; A F Roche; J H Himes
Journal:  Am J Clin Nutr       Date:  1986-05       Impact factor: 7.045

4.  Incremental growth charts.

Authors:  A F Roche; J H Himes
Journal:  Am J Clin Nutr       Date:  1980-09       Impact factor: 7.045

5.  A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.

Authors:  M W Kline; R B Van Dyke; J C Lindsey; M Gwynne; M Culnane; R E McKinney; S Nichols; W G Mitchell; R Yogev; N Hutcheon
Journal:  Pediatrics       Date:  1998-02       Impact factor: 7.124

6.  Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.

Authors:  S S Bakshi; P Britto; E Capparelli; L Mofenson; M G Fowler; S Rasheed; D Schoenfeld; B Zimmer; Y Frank; R Yogev; E Jimenez; M Salgo; G Boone; S G Pahwa
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

7.  Pediatric AIDS prognosis using somatic growth velocity.

Authors:  V J Carey; F H Yong; L M Frenkel; R E McKinney
Journal:  AIDS       Date:  1998-07-30       Impact factor: 4.177

8.  Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia.

Authors:  Carolyn Bolton-Moore; Mwangelwa Mubiana-Mbewe; Ronald A Cantrell; Namwinga Chintu; Elizabeth M Stringer; Benjamin H Chi; Moses Sinkala; Chipepo Kankasa; Craig M Wilson; Catherine M Wilfert; Albert Mwango; Jens Levy; Elaine J Abrams; Marc Bulterys; Jeffrey S A Stringer
Journal:  JAMA       Date:  2007-10-24       Impact factor: 56.272

9.  A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.

Authors:  R E McKinney; G M Johnson; K Stanley; F H Yong; A Keller; K J O'Donnell; P Brouwers; W G Mitchell; R Yogev; D W Wara; A Wiznia; L Mofenson; J McNamara; S A Spector
Journal:  J Pediatr       Date:  1998-10       Impact factor: 4.406

Review 10.  Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa.

Authors:  Catherine G Sutcliffe; Janneke H van Dijk; Carolyn Bolton; Deborah Persaud; William J Moss
Journal:  Lancet Infect Dis       Date:  2008-08       Impact factor: 25.071

View more
  15 in total

1.  Age-specific and sex-specific weight gain norms to monitor antiretroviral therapy in children in low-income and middle-income countries.

Authors:  Marcel Yotebieng; Tammy Meyers; Frieda Behets; Mary-Ann Davies; Olivia Keiser; Kapella Zacharia Ngonyani; Rita E Lyamuya; Azar Kariminia; Rawiwan Hansudewechakul; Valeriane Leroy; Sikiratou Koumakpai; Jamie Newman; Annelies Van Rie
Journal:  AIDS       Date:  2015-01-02       Impact factor: 4.177

2.  Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.

Authors:  Tammy M Meyers; Marcel Yotebieng; Louise Kuhn; Harry Moultrie
Journal:  Pediatr Infect Dis J       Date:  2011-11       Impact factor: 2.129

3.  CD4+ gain percentile curves for monitoring response to antiretroviral therapy in HIV-infected adults.

Authors:  Marcel Yotebieng; Mhairi Maskew; Annelies Van Rie
Journal:  AIDS       Date:  2015-06-01       Impact factor: 4.177

4.  Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in Tanzania.

Authors:  I Maro; T Lahey; T MacKenzie; L Mtei; M Bakari; M Matee; K Pallangyo; C F von Reyn
Journal:  Int J Tuberc Lung Dis       Date:  2010-11       Impact factor: 2.373

5.  Growth in Virologically Suppressed HIV-Positive Children on Antiretroviral Therapy: Individual and Population-level References.

Authors:  Olivia Keiser; Nello Blaser; Mary-Ann Davies; Patrick Wessa; Brian Eley; Harry Moultrie; Helena Rabie; Karl-Günther Technau; James Ndirangu; Daniela Garone; Janet Giddy; Ashraf Grimwood; Thomas Gsponer; Matthias Egger
Journal:  Pediatr Infect Dis J       Date:  2015-10       Impact factor: 2.129

6.  Effect of Age at Antiretroviral Therapy Initiation on Catch-up Growth Within the First 24 Months Among HIV-infected Children in the IeDEA West African Pediatric Cohort.

Authors:  Julie Jesson; Sikiratou Koumakpaï; Ndeye R Diagne; Madeleine Amorissani-Folquet; Fla Kouéta; Addi Aka; Koko Lawson-Evi; Fatoumata Dicko; Kouadio Kouakou; Touré Pety; Lorna Renner; Tanoh Eboua; Patrick A Coffie; Sophie Desmonde; Valériane Leroy
Journal:  Pediatr Infect Dis J       Date:  2015-07       Impact factor: 2.129

7.  Variability of growth in children starting antiretroviral treatment in southern Africa.

Authors:  Thomas Gsponer; Ralf Weigel; Mary-Ann Davies; Carolyn Bolton; Harry Moultrie; Paula Vaz; Helena Rabie; Karl Technau; James Ndirangu; Brian Eley; Daniela Garone; Maureen Wellington; Janet Giddy; Jochen Ehmer; Matthias Egger; Olivia Keiser
Journal:  Pediatrics       Date:  2012-09-17       Impact factor: 7.124

8.  Weight as predictors of clinical progression and treatment failure: results from the TREAT Asia Pediatric HIV Observational Database.

Authors:  Azar Kariminia; Nicolas Durier; Gonzague Jourdain; Suneeta Saghayam; Chau V Do; Lam Van Nguyen; Rawiwan Hansudewechakul; Pagakrong Lumbiganon; Kulkanya Chokephaibulkit; Khanh Huu Truong; Virat Sirisanthana; Vibol Ung; Saphonn Vonthanak; Jintanat Ananworanich; Nik Khairulddin Nik Yusoff; Nia Kurniati; Kamarul Azahar Razali; Moy Siew Fong; Revathy Nallusamy; Dewi Kumara Wati
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

9.  Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation.

Authors:  Sophie Desmonde; François T Eboua; Karen Malateste; Fatoumata Dicko; Didier K Ekouévi; Sylvie Ngbeché; Fla Koueta; Haby Signate Sy; Lorna Renner; Siriatou A Koumakpai; Valeriane Leroy
Journal:  AIDS       Date:  2015-07-31       Impact factor: 4.177

10.  Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: a cohort study.

Authors:  Catherine G Sutcliffe; Janneke H van Dijk; Bornface Munsanje; Francis Hamangaba; Pamela Sinywimaanzi; Philip E Thuma; William J Moss
Journal:  BMC Infect Dis       Date:  2011-03-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.